Home
中文
取消
Sperogenix
Sperogenix Therapeutics is a platform focusing on development and commercialization of Rare Diseases Medications in China , provide clinically accessible products for rare disease patients and successful commercial solutions for rare disease therapeutics in China.
Focus on Four Diseases Areas
Pulmonary Vascular Diseases
Neurological Diseases
Inherited Metabolic Diseases
Non-Onco Hematologic Diseases
Patients
Empowering Patients Communities

Patient-Centric and empowering patients communities

Pay attention to different aspects of patients' needs, and meet the challenges of diagnosis, treatment, rehabilitation and payment together with patients.

Supporting capacity building and resources linkage for patient groups, promoting sustainable development of patient organizations.

more
News
2024-03-26 18:26:37
Company
NDA of AGAMREE was Accepted and Granted Priority Review by China’s CDE
March 26, 2024, the NDA filling of AGAMREE (vamorolone) is indicated for the treatment of DMD in patients aged 4 years and older has been accepted by CDE of China NMPA, and been included in the “Priority Review Program.
2023-12-19 09:10:31
Company
Vamorolone was included in the "Breakthrough Therapy" program by the Center for Drug Evaluation of China NMPA
On September 16, 2023, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China announced that the new drug vamorolone was included in the "breakthrough therapy" program, and the proposed indication is for Duchenne muscular dystrophy (DMD) patients who are 2 years old and above.
2022-03-1 10:21:41
Company
Sperogenix Therapeutics and Luca Healthcare Announce a Strategic Collaboration to Develop Digital Therapeutics for Rare Diseases
Sperogenix Therapeutics and Luca Healthcare announced a strategic partnership to develop digital therapeutics for Sperogenix’s pipeline of rare disease treatments and improve overall treatment benefits.
more